ArticleCurrent pharmaceutical design2025
Synthetic Cannabinoids are Genotoxic in Cultured Human Lymphocytes.
Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSynthetic cannabinoids are one of the most identified abused drugs nowadays. Their popularity is due to their psychoactive effects, which resemble delta 9 tetrahydrocannabinol. This study investigates the genotoxic potential of three synthetic cannabinoids of indazole-passed drugs, AB-Fubinaca, AMBFubinaca, and EMB-Fubinaca (at a final concentration of 200 nM).
methodsGenotoxicity was examined using Sister Chromatid Exchanges (SCEs) and Chromosomal Aberrations (CAs) assays in cultured human lymphocytes. Blood for lymphocyte cultures was obtained from healthy adult young males.
resultsA significant increase in the frequency of SCEs was detected for all examined drugs (range: 5.4-6.1, p < 0.05) compared to the control group (4.70 ± 0.31). The order of synthetic cannabinoids in terms of their ability to induce SCEs was EMB-Fubinaca (6.04 ± 0.63) > AMB-Fubinaca (5.65 ± 0.6) > AB-Fubinaca (5.33 ± 0.58). None of the examined drugs induced significant changes to the frequency of CAs (p > 0.05). Additionally, there were no effects of the synthetic cannabinoids at the studied concentration on proliferation and mitotic indices.
conclusionSynthetic cannabinoids have been found to increase the frequency of SCEs in cultured human lymphocytes. The results should be confirmed in in vivo studies using lymphocytes derived from synthetic cannabinoid users.
Indexed as
Identifiers
39835562What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.